Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: Results of a meta-analysis of randomized controlled trials

Vox Sanguinis

Volumn 103, Issue 4, 2012, Pages 322-330

  Cid, J ^a   Escolar, G ^a   Lozano, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Meta analysis; Pathogen inactivation; Platelet transfusion

Indexed keywords

AMOTOSALEN;

ARTICLE; BACTERIUM; BLEEDING; BLOOD COMPONENT THERAPY; DOUBLE BLIND PROCEDURE; HUMAN; INFECTION RISK; LEUKOCYTE; LIGHT; META ANALYSIS; PRIORITY JOURNAL; PROTOZOON; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; ULTRAVIOLET IRRADIATION; VIRUS;

BLOOD PLATELETS; BLOOD PRESERVATION; HUMANS; PLATELET COUNT; PLATELET TRANSFUSION; PSORALENS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84867884006     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01614.x     Document Type: Article

References (38)

1. Schreiber GB, Busch MP, Kleinman SH, et al. : The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-1690
2. Klein HG, Dodd RY, Ness PM, et al. : Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997; 37:95-101
3. Leiby DA, Herron RM Jr, Read EJ, et al. : Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002; 42:549-555
4. Nichols WG, Price TH, Gooley T, et al. : Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101:4195-4200
5. Biggerstaff BJ, Petersen LR: Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion 2002; 42:1019-1026
6. Bianco C: Dengue and Chikungunya viruses in blood donations: risks to the blood supply? Transfusion 2008; 48:1279-1281
7. Yu XJ, Liang MF, Zhang SY, et al. : Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011; 364:1523-1532
8. Perkins HA, Busch MP: Transfusion-associated infections: 50years of relentless challenges and remarkable progress. Transfusion 2010; 50:2080-2099
9. Eder AF, Kennedy JM, Dy BA, et al. : Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554-1563
10. Dumont LJ, Kleinman S, Murphy JR, et al. : Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010; 50:589-599
11. Lozano M: Pathogen-inactivation technologies for blood components; in Blajchman M, Cid J, Lozano M (eds): Blood Component Preparation. From Benchtop to Bedside, 1st edn. Bethesda, MD, AABB Press, 2011:247-270
12. Klein HG: Pathogen inactivation: rationale and some history; in AuBuchon JP, Prowse CV (eds): Pathogen Inactivation. The Penultimate Paradigm Shift, 1st edn. Bethesda, MD, AABB Press, 2010:1-16
13. Lin L, Cook DN, Wiesehahn GP, et al. : Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-435
14. Snyder E, Raife T, Lin L, et al. : Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44:1732-1740
15. Slichter SJ, Raife TJ, Davis K, et al. : Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46:731-740
16. Lozano M, Galan A, Mazzara R, et al. : Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47:666-671
17. van Rhenen D, Gulliksson H, Cazenave JP, et al. : Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426-2433
18. McCullough J, Vesole DH, Benjamin RJ, et al. : Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534-1541
19. Janetzko K, Cazenave JP, Kluter H, et al. : Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45:1443-1452
20. Kerkhoffs JL, van Putten WL, Novotny VM, et al. : Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209-217
21. Lozano M, Knutson F, Tardivel R, et al. : A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153:393-401
22. Vamvakas EC: Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51:1058-1071
23. Vamvakas EC: Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102:302-316
24. Robinson KA, Dickersin K: Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31:150-153
25. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. : A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005; 34:224-225
26. Jadad AR, Moore RA, Carroll D, et al. : Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12
27. Heddle NM, Arnold DM, Webert KE: Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion 2011; 51:430-434
28. Heddle NM, Cook RJ, Webert KE, et al. : Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43:742-752
29. Heddle NM, Wu C, Vassallo R, et al. : Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion 2011; 51:2304-2310
30. Egger M, Smith GD: Problems and limitations in conducting systematic reviews; in Egger M, Smith GD, Altman DG (eds): Systematic Reviews in Health Care. Meta-Analysis in Context, 2nd edn. London, BMJ, 2001:43-68
31. Clarke MJ, Stewart LA: Obtaining individual patient data from randomised controlled trials; in Egger M, Smith GD, Altman DG (eds): Systematic Reviews in Health Care. Meta-Analysis in Context, 2nd edn. London, BMJ, 2001:109-121
32. Thompson SG, Pocock SJ: Can meta-analyses be trusted? Lancet 1991; 338:1127-1130
33. Vamvakas EC: Applications of meta-analysis in transfusion medicine; in Vamvakas EC (ed): Evidence-Based Practice of Transfusion Medicine, 1st edn. Bethesda, MD, AABB Press, 2001:221-258
34. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558
35. Higgins JP, Thompson SG, Deeks JJ, et al. : Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560
36. Lozano M, Cid J: The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17:57-68
37. Cid J, Lozano M: Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion 2007; 47:464-470
38. The Mirasol Clinical Evaluation Study Group: A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50:2362-2375